Kymera Therapeutics (KYMR) Analyst & Key Data

Analyst Consensus

Buy46 analysts

Buy

Updated Sep 12, 2026

Total Analysts46

Buy

24

Hold

3

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$114.96

Median Target-3.94%

$110.43

Potential downside vs current price

DCF Value-99.83%

$0.19

Potential downside vs current price

Current Stock Price

$114.96

Median Target-3.94%

$110.43

Potential downside vs current price

DCF Value-99.83%

$0.19

Potential downside vs current price

Analyst Consensus

Buy46 analysts

Buy

Updated Sep 12, 2026

Total Analysts46

Buy

24

Hold

3

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$114.96

Median Target-3.94%

$110.43

Potential downside vs current price

DCF Value-99.83%

$0.19

Potential downside vs current price

Current Stock Price

$114.96

Median Target-3.94%

$110.43

Potential downside vs current price

DCF Value-99.83%

$0.19

Potential downside vs current price

Kymera Therapeutics, Inc.